Ipilimumab • Recombinant monoclonal antibody to CTLA4. Ipilimumab (known as MDX-010 and MDX-101), marketed as Yervoy, is a drug used for the treatment of melanoma, a type of skin cancer. It is a U.S. Food and Drug Administration (FDA) approved human monoclonal antibody, and works by activating the immune system by targeting CTLA-4. • Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism that interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy cancer cells.
Search
Read the Text Version
- 1 - 1
Pages:
